DHR
Danaher
Stock NYSE – Stock Market Prices, News & Analysis
Danaher Corp is a global company engaged in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services, particularly in biotechnology and diagnostics.
Danaher
DHR
Danaher Corp is a global company engaged in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services, particularly in biotechnology and diagnostics.
Price history of Danaher
Price history of Danaher
Performance & Momentum
Danaher to Acquire Masimo for $9.9B
Danaher Corporation (NYSE: DHR) has announced a cash acquisition of Masimo Corporation (NASDAQ: MASI) for approximately $9.9 billion, valuing Masimo at $180 per share. The deal, unanimously approved by both companies' boards, will integrate Masimo as an autonomous entity within Danaher's Diagnostics segment. Additionally, Danaher is maintaining a stable dividend policy, continuing a quarterly payout of $0.40 per share, reassuring investors despite recent relatively weak stock performance. This acquisition strengthens Danaher's position in life sciences and is expected to support the market’s anticipated recovery.
Strategic Analysis
Danaher • 2026
Danaher Corp relies on an integrated model combining biotechnology and medical technology, offering a wide range of innovative products and services in the healthcare sector. Its industrial diversification and global positioning enable it to capitalize on structural trends in healthcare and applied sciences.
Strengths
- Diversified portfolio including high-value-added biotechnology and diagnostics
- Global presence providing resilience against local economic cycles
- Sustained innovation capacity, fostering the adoption of advanced medical technologies
Weaknesses
- Sensitivity to complex regulatory fluctuations in multiple jurisdictions
- Recent stock performance moderately volatile with a return to stability in the medium term
Momentum
The momentum shows an intermediate level, indicating moderate investor interest. After solid performance over the past six months, the stock is showing marked stabilization in the longer term, suggesting a consolidation period. This dynamic invites a cautious approach while remaining attentive to potential catalysts in the medical sector.
Similar stocks to Danaher
Recent News
Danaher
Danaher Confirms Upbeat Outlook for 2026
2 months agoDanaher continues to impress investors with strong optimism for 2026. The company anticipates adjusted non-GAAP revenues and earnings by the end of 2025 to reach the high end of its estimates, driven by its bioprocessing, life sciences, and diagnostics segments. Additionally, its subsidiary Integrated DNA Technologies is expanding its synthetic biology portfolio through a strategic partnership with Ansa Biotechnologies, enhancing its innovative capabilities. Analysts, including TD Cowen, maintain a buy rating with an upwardly revised price target, highlighting strong potential amid economic uncertainty.
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
